CSL Limited has signed an exclusive licensing deal with Swiss biotech Alentis Therapeutics to develop and commercialize lixudebart, a drug in Phase 2 trials for rare autoimmune kidney disease ANCA-associated vasculitis. The drug targets inflammation and fibrosis, key factors in organ damage, and CSL aims to expand its kidney disease portfolio by also exploring treatments for FSGS and PSC. CSL will pay $355 million upfront and up to $1.2 billion in milestones, funding all clinical development, and will retain 55% of profits if the drug reaches market.
CSL's $1.6 billion licensing deal for a rare disease drug provides context for health sector activity. For readers following the health sector, here is Pluang's market snapshot as of Oct 05, 2026 04:51 WIB: out of 100 priced US health stocks, 49 rose and 48 fell. Among notable movers, Adaptive Biotechnologies Corp (ADPT) rose 3.58% to USD 28.35 with a typical hold time of 36 days, Oscar Health Inc (OSCR) increased 3.48% to USD 30.94 with a hold time of 15 days, while Cassava Sciences Inc (FLNA) declined 3.53% to USD 0.93 with a typical hold time of 37 days.
U.S. President Donald Trump warned South Korea to sign on soon to the $50 billion Alaska LNG project or face higher charges, possibly tariffs, though he did not specify details. South Korea is still evaluating the project based on commercial viabilit...
Zcash has registered a lobbyist in Washington, DC, aiming to influence US cryptocurrency policies, including tax rules and market structure. This move is part of Zcash's effort to promote privacy-focused crypto regulations. Market watchers see this a...
GraniteShares 2x Long MU Daily ETF (MULL), which offers double the daily performance of Micron stock, is rated Hold due to expected short-term volatility. Micron's growth prospects remain strong, supported by expanding production capacity, high deman...
A wallet holding a large short position of about 78,000 Ether (ETH) on Hyperliquid experienced an unrealized loss of approximately $30.29 million as of October 5. The position was valued at around $213 million with an average opening price of $2,340 ...
Bitcoin's price climbed to $86,771 on October 4, closing in on the recent high of $87,177 from the previous Friday. Historically, October has been a strong month for Bitcoin, with gains in 10 of the last 13 years and a median increase of 12.7%, sugge...
